Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 13 de 13
Filtrar
1.
Endocrinol Metab Clin North Am ; 37(3): 647-62, ix, 2008 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-18775357

RESUMEN

Hypertension and obesity are major components of the cardiometabolic syndrome and are both on the rise worldwide, with enormous consequences on global health and the economy. The relationship between hypertension and obesity is multifaceted; the etiology is complex and it is not well elucidated. This article, reviews the current knowledge on obesity-related hypertension. Further understanding of the underlying mechanisms of this epidemic will be important in devising future treatment avenues.


Asunto(s)
Hipertensión/etiología , Obesidad/complicaciones , Adipocitos/fisiología , Adiponectina/fisiología , Animales , Humanos , Resistencia a la Insulina , Riñón/patología , Riñón/fisiopatología , Leptina/fisiología , Obesidad/fisiopatología , Sistema Renina-Angiotensina/fisiología , Apnea Obstructiva del Sueño/fisiopatología , Sistema Nervioso Simpático/fisiología
2.
Exp Biol Med (Maywood) ; 233(9): 1109-23, 2008 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-18641056

RESUMEN

CONTEXT: The transgenic human islet amyloid polypeptide (HIP) rat model of type 2 diabetes mellitus (T2DM) parallels the functional and structural changes in human islets with T2DM. OBJECTIVE: The transmission electron microscope (TEM) was utilized to observe the ultrastructural changes in islet microcirculation. METHODS: Pancreatic tissue from male Sprague Dawley rats (2, 4, 8, 14 months) were used as controls (SDC) and compared to the 2-, 4-, 8- and 14-month-old HIP rat models. RESULTS: The 2-month-old HIP model demonstrated no islet or microcirculation remodeling changes when compared to the SDC models. The 4-month-old HIP model demonstrated significant pericapillary amyloid deposition and diminution of pericyte foot processes as compared to the SDC models. The 8-month-old model demonstrated extensive islet amyloid deposition associated with pericyte and beta-cell apoptosis when compared with SDC. The 14-month-old HIP model demonstrated a marked reduction of beta-cells and intra-islet capillaries with near complete replacement of islets by amyloidoses. Increased cellularity in the region of the islet exocrine interface was noted in the 4- to 14-month-old HIP models as compared to SDC. In contrast to intra-islet capillary rarefaction there was noticeable angiogenesis in the islet exocrine interface. Pericytes seemed to be closely associated with collagenosis, intra-islet adipogenesis and angiogenesis in the islet exocrine interface. CONCLUSION: The above novel findings regarding the microcirculation and pericytes could assist researchers and clinicians in a better morphological understanding of T2DM and lead to new strategies for prevention and treatment of T2DM.


Asunto(s)
Amiloide/metabolismo , Diabetes Mellitus Tipo 2/patología , Páncreas Exocrino/ultraestructura , Enfermedades Pancreáticas/patología , Péptidos/metabolismo , Pericitos/ultraestructura , Actinas/metabolismo , Envejecimiento/fisiología , Animales , Anticuerpos/inmunología , Glucemia/metabolismo , Diabetes Mellitus Tipo 2/metabolismo , Modelos Animales de Enfermedad , Humanos , Masculino , Microcirculación , Microscopía Electrónica de Transmisión , Músculo Liso/metabolismo , Factor de Crecimiento Derivado de Plaquetas/inmunología , Factor de Crecimiento Derivado de Plaquetas/metabolismo , Ratas , Ratas Sprague-Dawley , Receptores del Factor de Crecimiento Derivado de Plaquetas/metabolismo
3.
Curr Hypertens Rep ; 10(4): 319-25, 2008 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-18625163

RESUMEN

Insulin resistance, cardiometabolic syndrome, and hypertension are common health problems with significant consequences for individuals and society. The pathogenesis of these disorders is complex and not fully understood. In this article we review the current knowledge about the effects of lifestyle modification and pharmacologic antihypertensive agents on insulin resistance and hypertension.


Asunto(s)
Hipertensión/tratamiento farmacológico , Hipertensión/fisiopatología , Resistencia a la Insulina/fisiología , Antagonistas Adrenérgicos beta/uso terapéutico , Bloqueadores del Receptor Tipo 1 de Angiotensina II/uso terapéutico , Inhibidores de la Enzima Convertidora de Angiotensina/uso terapéutico , Antihipertensivos/uso terapéutico , Fármacos Cardiovasculares/uso terapéutico , Endotelio Vascular/fisiopatología , Humanos , Inflamación/fisiopatología , Estilo de Vida , Antagonistas de Receptores de Mineralocorticoides , Obesidad/fisiopatología , Renina/antagonistas & inhibidores , Sistema Renina-Angiotensina/fisiología
4.
Endocrinology ; 148(8): 3773-80, 2007 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-17494996

RESUMEN

The renin-angiotensin-aldosterone system contributes to cardiac remodeling, hypertrophy, and left ventricular dysfunction. Angiotensin II and aldosterone (corticosterone in rodents) together generate reactive oxygen species (ROS) via reduced nicotinamide adenine dinucleotide phosphate (NADPH) oxidase, which likely facilitate this hypertrophy and remodeling. This investigation sought to determine whether cardiac oxidative stress and cellular remodeling could be attenuated by in vivo mineralocorticoid receptor (MR) blockade in a rodent model of the chronically elevated tissue renin-angiotensin-aldosterone system, the transgenic TG (mRen2) 27 rat (Ren2). The Ren2 overexpresses the mouse renin transgene with resultant hypertension, insulin resistance, proteinuria, and cardiovascular damage. Young (6- to 7-wk-old) male Ren2 and age-matched Sprague-Dawley rats were treated with spironolactone or placebo for 3 wk. Heart tissue ROS, immunohistochemical analysis of 3-nitrotyrosine, and NADPH oxidase (NOX) subunits (gp91(phox) recently renamed NOX2, p22(phox), Rac1, NOX1, and NOX4) were measured. Structural changes were assessed with cine-magnetic resonance imaging, transmission electron microscopy, and light microscopy. Significant increases in Ren2 septal wall thickness (cine-magnetic resonance imaging) were accompanied by perivascular fibrosis, increased mitochondria, and other ultrastructural changes visible by light microscopy and transmission electron microscopy. Although there was no significant reduction in systolic blood pressure, significant improvements were seen with MR blockade on ROS formation and NOX subunits (each P < 0.05). Collectively, these data suggest that MR blockade, independent of systolic blood pressure reduction, improves cardiac oxidative stress-induced structural and functional changes, which are driven, in part, by angiotensin type 1 receptor-mediated increases in NOX.


Asunto(s)
Cardiomegalia/tratamiento farmacológico , Antagonistas de Receptores de Mineralocorticoides/farmacología , NADPH Oxidasas/metabolismo , Espironolactona/farmacología , Remodelación Ventricular/efectos de los fármacos , Animales , Animales Modificados Genéticamente , Presión Sanguínea/fisiología , Cardiomegalia/metabolismo , Cardiomegalia/patología , Enfermedad Crónica , Fibrosis , Imagen por Resonancia Magnética , Masculino , Microscopía Electrónica de Transmisión , Mitocondrias/metabolismo , Mitocondrias/patología , Mitocondrias/ultraestructura , Miocardio/metabolismo , Miocardio/patología , Miocitos Cardíacos/metabolismo , Miocitos Cardíacos/patología , Miocitos Cardíacos/ultraestructura , Estrés Oxidativo/fisiología , Ratas , Ratas Sprague-Dawley , Receptores de Mineralocorticoides/metabolismo , Renina/genética , Renina/metabolismo , Sistema Renina-Angiotensina/efectos de los fármacos , Sistema Renina-Angiotensina/fisiología , Disfunción Ventricular Izquierda/tratamiento farmacológico , Disfunción Ventricular Izquierda/metabolismo , Disfunción Ventricular Izquierda/patología , Remodelación Ventricular/fisiología
5.
JOP ; 8(6): 725-38, 2007 Nov 09.
Artículo en Inglés | MEDLINE | ID: mdl-17993725

RESUMEN

CONTEXT: Type 2 diabetes mellitus is a multifactorial disease with polygenic and environmental stressors resulting in multiple metabolic toxicities and islet oxidative stress. We have integrated the role of the islet renin-angiotensin system (RAS) in the pathogenesis of early islet fibrosis utilizing the transgenic (mRen2)27 rodent model of hypertension and tissue RAS overexpression. OBJECTIVE: The Ren2 pancreatic islet tissue was evaluated with transmission electron microscopy to study both early cellular and extracellular matrix remodeling. ANIMALS: Four 9- to 10-week-old male Ren2 untreated models and four Sprague Dawley sex and age matched controls were used. DESIGN: Ultrastructural study to compare pancreatic islet tissue. MAIN OUTCOME MEASURES: Only qualitative and observational transmission electron microscopy findings are reported. RESULTS: Major remodeling differences in the Ren2 model were found to be located within the islet exocrine interface, including deposition of early fibrillar-banded collagen (fibrosis) and cellular remodeling of the pericyte suggesting proliferation, migration, hypertrophy and activation as compared to the Sprague Dawley controls. CONCLUSION: This study points to the possibility of the pericyte cell being one of many contributors to the fibrogenic pool of cells important for peri-islet fibrosis as a result of excess angiotensin II at the local tissue level in the Ren2 model. These findings suggest that the pericyte may be capable of differentiating into the pancreatic stellate cell. This islet ultrastructure study supports the notion that pericyte cells could be the link between islet vascular oxidative stress and peri-islet fibrosis. Pericyte-endothelial-pancreatic stellate cell associations and morphology are discussed.


Asunto(s)
Hipertensión/patología , Islotes Pancreáticos/patología , Islotes Pancreáticos/ultraestructura , Pericitos/patología , Sistema Renina-Angiotensina/fisiología , Angiotensina II/metabolismo , Animales , Animales Modificados Genéticamente , Glucemia/fisiología , Presión Sanguínea/fisiología , Peso Corporal/fisiología , Comunicación Celular/fisiología , Modelos Animales de Enfermedad , Matriz Extracelular/patología , Matriz Extracelular/fisiología , Matriz Extracelular/ultraestructura , Fibrosis , Hipertensión/fisiopatología , Islotes Pancreáticos/metabolismo , Masculino , Estrés Oxidativo/fisiología , Pericitos/fisiología , Ratas , Ratas Sprague-Dawley , Sistema Renina-Angiotensina/genética
7.
Med Clin North Am ; 95(5): 903-17, 2011 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-21855699

RESUMEN

Obesity and HTN are on the rise in the world. HTN seems to be the most common obesity-related health problem and visceral obesity seems to be the major culprit. Unfortunately, only 31% of hypertensives are treated to goal. This translates into an increased incidence of CVD and related morbidity and mortality. Several mechanisms have been postulated as the causes of obesity-related HTN. Activation of the RAAS, SNS, insulin resistance, leptin, adiponectin, dysfunctional fat, FFA, resistin, 11 Beta dehydrogenase, renal structural and hemodynamic changes, and OSA are some of the abnormalities in obesity-related HTN. Many of these factors are interrelated. Treatment of obesity should begin with weight loss via lifestyle modifications, medications, or bariatric surgery. According to the mechanisms of obesity-related HTN, it seems that drugs that blockade the RAAS and target the SNS should be ideal for treatment. There is not much evidence in the literature that one drug is better than another in controlling obesity-related HTN. There have only been a few studies specifically targeting the obese hypertensive patient, but recent trials that emphasize the importance of BP control have enrolled both overweight and obese subjects. Until we have further studies with more in-depth information about the mechanisms of obesity-related HTN and what the targeted treatment should be, the most important factor necessary to control the obesity-related HTN pandemic and its CVD and CKD consequences is to prevent and treat obesity and to treat HTN to goal.


Asunto(s)
Hipertensión/etiología , Resistencia a la Insulina/fisiología , Obesidad/fisiopatología , Adipocitos/metabolismo , Humanos , Hipertensión/fisiopatología , Fallo Renal Crónico/etiología , Fallo Renal Crónico/fisiopatología , Obesidad/complicaciones , Sistema Renina-Angiotensina/fisiología , Apnea Obstructiva del Sueño/etiología , Apnea Obstructiva del Sueño/fisiopatología , Sistema Nervioso Simpático/metabolismo
8.
Am J Physiol Heart Circ Physiol ; 293(4): H2009-23, 2007 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-17586614

RESUMEN

Hypertension commonly occurs in conjunction with insulin resistance and other components of the cardiometabolic syndrome. Insulin resistance plays a significant role in the relationship between hypertension, Type 2 diabetes mellitus, chronic kidney disease, and cardiovascular disease. There is accumulating evidence that insulin resistance occurs in cardiovascular and renal tissue as well as in classical metabolic tissues (i.e., skeletal muscle, liver, and adipose tissue). Activation of the renin-angiotensin-aldosterone system and subsequent elevations in angiotensin II and aldosterone, as seen in cardiometabolic syndrome, contribute to altered insulin/IGF-1 signaling pathways and reactive oxygen species formation to induce endothelial dysfunction and cardiovascular disease. This review examines currently understood mechanisms underlying the development of resistance to the metabolic actions of insulin in cardiovascular as well as skeletal muscle tissue.


Asunto(s)
Enfermedades Cardiovasculares/etiología , Resistencia a la Insulina , Síndrome Metabólico/metabolismo , Estrés Oxidativo , Sistema Renina-Angiotensina , Angiotensina II/metabolismo , Animales , Enfermedades Cardiovasculares/metabolismo , Enfermedades Cardiovasculares/fisiopatología , Enfermedad Crónica , Diabetes Mellitus Tipo 2/complicaciones , Diabetes Mellitus Tipo 2/metabolismo , Diabetes Mellitus Tipo 2/fisiopatología , Endotelio Vascular/metabolismo , Endotelio Vascular/fisiopatología , Humanos , Hipertensión/complicaciones , Hipertensión/metabolismo , Hipertensión/fisiopatología , Insulina/metabolismo , Factor I del Crecimiento Similar a la Insulina/metabolismo , Enfermedades Renales/complicaciones , Enfermedades Renales/metabolismo , Enfermedades Renales/fisiopatología , Síndrome Metabólico/complicaciones , Síndrome Metabólico/fisiopatología , Mineralocorticoides/metabolismo , Músculo Esquelético/metabolismo , Músculo Esquelético/fisiopatología , Miocardio/metabolismo , Especies Reactivas de Oxígeno/metabolismo , Receptor de Angiotensina Tipo 1/metabolismo , Factores de Riesgo , Transducción de Señal
9.
Curr Hypertens Rep ; 8(5): 403-8, 2006 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-16965727

RESUMEN

Treatment of hypertension with the major available antihypertensive classes results in a significant improvement in cardiovascular morbidity and mortality. However, there is controversy about whether specific classes of drug therapy have deleterious or beneficial effects on glucose and lipid metabolism. Myths and misconceptions have thus arisen. Although "old" classes of antihypertensives, such as diuretics and beta-blockers, seem to have deleterious effects on glucose and lipid metabolism, the "newer" agents appear to have either neutral or beneficial profiles. The long-term significance of these metabolic changes is still debated. It is known that insulin resistance plays a major role in the pathogenesis of hypertension and type 2 diabetes mellitus. There is increasing evidence that blocking the renin-angiotensin-aldosterone system by using angiotensin-converting enzyme inhibitors or angiotensin-receptor blockers favorably affects insulin sensitivity and, accordingly, decreases the incidence of new-onset type 2 diabetes mellitus.


Asunto(s)
Antihipertensivos/efectos adversos , Diabetes Mellitus Tipo 2/inducido químicamente , Hiperlipidemias/inducido químicamente , Hipertensión/tratamiento farmacológico , Resistencia a la Insulina , Bloqueadores del Receptor Tipo 1 de Angiotensina II/efectos adversos , Bloqueadores del Receptor Tipo 1 de Angiotensina II/uso terapéutico , Inhibidores de la Enzima Convertidora de Angiotensina/efectos adversos , Inhibidores de la Enzima Convertidora de Angiotensina/uso terapéutico , Antihipertensivos/uso terapéutico , Diabetes Mellitus Tipo 2/prevención & control , Estudios de Seguimiento , Humanos , Hiperlipidemias/prevención & control , Resistencia a la Insulina/fisiología , Ensayos Clínicos Controlados Aleatorios como Asunto , Factores de Riesgo
10.
J Cardiometab Syndr ; 1(2): 125-30; quiz 131-2, 2006.
Artículo en Inglés | MEDLINE | ID: mdl-17679815

RESUMEN

Polycystic ovarian syndrome (PCOS) is the most common reproductive endocrinopathy of women during their childbearing years. A significant degree of controversy exists regarding the etiology of this syndrome, but there is a growing consensus that the key features include insulin resistance, androgen excess, and abnormal gonadotropin dynamics. Familial and genetic factors cause predisposition to PCOS. Insulin resistance and adiposity put women with PCOS at a higher risk for diabetes, hypertension, dyslipidemia, and cardiovascular disease. Even though the adverse health consequences associated with PCOS are substantial, most women are not aware of these risks. Early recognition and treatment of metabolic sequelae should be the main focus of clinicians. Lifestyle modifications, mainly a balanced diet, weight loss, and regular exercise, are of utmost importance. On the pharmacologic front, various therapies including metformin, thiazolidinediones, and others appear to be very promising in the management of cardiometabolic aspects of PCOS.


Asunto(s)
Enfermedades Cardiovasculares/etiología , Síndrome Metabólico/complicaciones , Síndrome del Ovario Poliquístico/complicaciones , Síndrome del Ovario Poliquístico/fisiopatología , Glándulas Suprarrenales/fisiopatología , Enfermedades Cardiovasculares/fisiopatología , Diabetes Mellitus Tipo 2/complicaciones , Diagnóstico Diferencial , Dislipidemias/complicaciones , Femenino , Predisposición Genética a la Enfermedad , Humanos , Hiperandrogenismo , Hipertensión/complicaciones , Sistema Hipotálamo-Hipofisario/fisiopatología , Resistencia a la Insulina , Síndrome Metabólico/etiología , Síndrome Metabólico/fisiopatología , Obesidad/complicaciones , Ovario/fisiopatología , Síndrome del Ovario Poliquístico/diagnóstico , Síndrome del Ovario Poliquístico/etiología , Síndrome del Ovario Poliquístico/terapia , Factores de Riesgo , Resultado del Tratamiento
11.
J Am Soc Nephrol ; 15(11): 2816-27, 2004 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-15504934

RESUMEN

The incidence of end-stage renal disease (ESRD) has risen dramatically in the past decade, mainly due to the increasing prevalence of diabetes mellitus, and both impaired glucose tolerance and hypertension are important contributors to rising rates of ESRD. Obesity, especially the visceral type, is associated with peripheral resistance to insulin actions and hyperinsulinemia, which predisposes to development of diabetes. A common genetic predisposition to insulin resistance and hypertension and the coexistence of these two disorders predisposes to premature atherosclerosis. A constellation of metabolic and cardiovascular derangements, which also includes dyslipidemia, dysglycemia, endothelial dysfunction, fibrinolytic and inflammatory abnormalities, left ventricular hypertrophy, microalbuminuria, and increased oxidative stress, is referred to as the cardiometabolic syndrome. The components of this syndrome, individually and interdependently, substantially increase the risk of renal disease, cardiovascular disease (CVD) and mortality. Similar findings and cardiorenal risk factors can occur in subjects with android obesity without excess body weight.Recently, microalbuminuria has been gaining momentum as a component and marker for the cardiometabolic syndrome, in addition to being an early marker for progressive renal disease in patients with this syndrome or in those with diabetes. Furthermore, it is now established as an independent predictor of CVD and CVD mortality. This review examines the relationship between insulin resistance/hyperinsulinemia and hypertension in the context of cardiometabolic syndrome, progressive renal disease and accelerated CVD. The importance of microalbuminuria as an early marker for the cardiometabolic syndrome is also discussed in this review.


Asunto(s)
Hiperinsulinismo/complicaciones , Hipertensión/complicaciones , Enfermedades Renales/etiología , Enfermedades Renales/fisiopatología , Animales , Enfermedades Cardiovasculares/etiología , Enfermedades Cardiovasculares/mortalidad , Progresión de la Enfermedad , Humanos , Obesidad/complicaciones
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA